Bavarian Nordic AS - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Bavarian Nordic AS Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Bavarian Nordic AS. The Group's principal activities are development and production of vaccines and immune therapy products. The Group applies gene therapy and new methodologies in vaccine delivery. The Group utilises three proprietary delivery technologies for its product development programmes: a pox virus vector, a retroviral vector and a cell encapsulation technology. The main product of the Group is the manufacture of smallpox vaccine. The ongoing clinical programmes involve HIV, malignant melanoma, smallpox and cancer research. The Group operates in Denmark, Germany, the US and Singapore.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report